Short Interest in Genprex (NASDAQ:GNPX) Expands By 121.9%

Genprex (NASDAQ:GNPX) saw a significant growth in short interest in April. As of April 30th, there was short interest totaling 1,121,624 shares, a growth of 121.9% from the April 15th total of 505,519 shares. Approximately 10.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,951,059 shares, the short-interest ratio is presently 0.6 days.

Genprex Stock Down 3.6%

Shares of NASDAQ:GNPX traded down $0.03 during midday trading on Friday, reaching $0.83. The company’s stock had a trading volume of 191,156 shares, compared to its average volume of 1,253,202. The firm has a market cap of $8.79 million, a price-to-earnings ratio of -0.03 and a beta of -0.94. Genprex has a 1 year low of $0.81 and a 1 year high of $55.00. The business has a 50 day moving average price of $1.42 and a 200 day moving average price of $2.35.

Genprex (NASDAQ:GNPX) last released its earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Several equities analysts have weighed in on GNPX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a research report on Tuesday, April 21st. Wall Street Zen upgraded shares of Genprex from a “sell” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Investors Weigh In On Genprex

A number of institutional investors have recently added to or reduced their stakes in GNPX. Susquehanna International Group LLP grew its position in Genprex by 11.7% during the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after acquiring an additional 35,661 shares during the period. Mayflower Financial Advisors LLC purchased a new stake in Genprex during the first quarter valued at about $36,000. Finally, Manchester Financial Inc. purchased a new stake in Genprex during the first quarter valued at about $36,000. Hedge funds and other institutional investors own 14.05% of the company’s stock.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.